NVAXHIGH SIGNALFINANCIAL10-K

Novavax achieved a dramatic turnaround from a $187.5M net loss to $440.3M profit with 65% revenue growth, but faces concerning cash burn acceleration and significant balance sheet deterioration.

This represents a remarkable operational transformation with the company moving from deep losses to substantial profitability while dramatically cutting SG&A expenses by over 50%. However, the 180% deterioration in operating cash flow to -$244.6M combined with cash reserves dropping 55% to $240.6M creates potential liquidity concerns that could overshadow the profitability gains.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

Novavax delivered exceptional top-line growth with revenue jumping 65% to $1.1B and achieved a stunning profit turnaround of over $600M through aggressive cost cutting that reduced SG&A by 53%. However, the balance sheet shows stress with cash declining 55% to $240.6M, operating cash flow worsening significantly to -$244.6M, and current liabilities remaining elevated at $459.9M despite improvement. The disconnect between strong reported profits and deteriorating cash generation, combined with the company's dwindling cash position, signals potential working capital or timing issues that investors should monitor closely.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+334.8%
-$187.5M$440.3M

Net income grew 334.8% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+281.9%
-$248.9M$452.8M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
-180.3%
-$87.3M-$244.6M

Operating cash flow fell 180.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Accounts Receivable
Balance Sheet
-83.9%
$1.4M$233K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Stockholders Equity
Balance Sheet
+79.5%
-$623.8M-$127.8M

Equity base grew 79.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Revenue
P&L
+64.7%
$682.2M$1.1B

Strong top-line growth of 64.7% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
-60.2%
$1.2B$459.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Cash & Equivalents
Balance Sheet
-54.6%
$530.2M$240.6M

Cash declined 54.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

SG&A Expense
P&L
-53.3%
$337.2M$157.5M

SG&A reduced 53.3% — improved cost efficiency or headcount reduction improving operating margins.

Total Liabilities
Balance Sheet
-40.3%
$2.2B$1.3B

Liabilities reduced 40.3% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
As of February 16, 2026, there were 162,935,945 shares of the registrant s common stock outstanding.
All references in this Annual Report on Form 10-K to Nuvaxovid TM or COVID-19 Vaccine refer to the Nuvaxovid COVID-19 vaccine; all references to "JN.1 COVID-19 Vaccine" refer to the Nuvaxovid TM COVID-19 Vaccine for the 2025-2026 vaccination season.
SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS Our business is subject to numerous risks.
The following is a summary of the principal risk factors described in this section: We have a history of losses and our future profitability is uncertain.
Our existing collaboration, funding and supply agreements, including the Sanofi CLA and our APAs, do not assure success of our vaccine candidates or vaccines or that we will be able to fully fund our vaccine candidates or vaccines or our operations, and if we are unable to satisfy the performance obligations under such agreements, we may not be eligible to receive milestone payments under such agreements, the agreements may be terminated, the purchase commitments may be reduced or we may be required to refund advance payments.
+7 more — sign up free →
REMOVED
As of February 18, 2025, there were 160,844,197 shares of the Registrant s common stock outstanding.
FORM 10-K SUMMARY 95 2 Table o f Contents CERTAIN DEFINITIONS All references in this Annual Report on Form 10-K to Novavax, the Company, we, us, and our refer to Novavax, Inc.
All references in this Annual Report on Form 10-K to "NVX-CoV2373 or prototype COVID-19 vaccine refer to our Nuvaxovid prototype COVID-19 vaccine; all references to "NVX-CoV2601" or "XBB COVID-19 vaccine" refer to our Nuvaxovid TM COVID-19 vaccine for the 2023-2024 vaccination season; and all references to "NVX-CoV2705", "JN.1 COVID-19 vaccine" or updated COVID-19 vaccine refer to our Nuvaxovid TM COVID-19 vaccine for the 2024-2025 vaccination season.
We refer to our prototype COVID-19 vaccine and updated COVID-19 vaccines, collectively, as our COVID-19 vaccine .
Local regulatory authorities have also specified nomenclature for our COVID-19 vaccine for labeling within their territories (e.g., Novavax COVID-19 Vaccine, Adjuvanted , Novavax COVID-19, Adjuvanted (2023-2024 or 2024-2025 Formula), respectively, for the U.S., and Nuvaxovid for ex-U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →